Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 19/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746388 | 0.95 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2283833 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1389222 | 0.91 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL12375770 | 0.88 | ADORA3 (0.88) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL958405 | 0.86 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2288712 | 0.85 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1389184 | 0.85 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1389176 | 0.84 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1389191 | 0.84 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL2284068 | 0.83 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203719-A1 | ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS | BOREA PIER ANDREA | 2009-08-13 | — | — | US | disclosed |
| US-20090203719-A1 | ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS | BOREA PIER ANDREA | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203719-A1 | ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A3 ANTAGONISTS | ADORA3, ADORA2A, ABCB1 | ADORA3 1/4885ADORA2A 2/4885ADORA2B 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.